Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Apollomics Inc. Class A Ordinary Shares (APLM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: APLM (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $2
1 Year Target Price $2
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -25.83% | Avg. Invested days 11 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 7.18M USD | Price to earnings Ratio - | 1Y Target Price 2 |
Price to earnings Ratio - | 1Y Target Price 2 | ||
Volume (30-day avg) 1 | Beta 0.88 | 52 Weeks Range 4.47 - 28.90 | Updated Date 06/30/2025 |
52 Weeks Range 4.47 - 28.90 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -52.8 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) 1007.39% |
Management Effectiveness
Return on Assets (TTM) -75.07% | Return on Equity (TTM) -233.67% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -1617205 | Price to Sales(TTM) 36.28 |
Enterprise Value -1617205 | Price to Sales(TTM) 36.28 | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.1 | Shares Outstanding 1103350 | Shares Floating 773105 |
Shares Outstanding 1103350 | Shares Floating 773105 | ||
Percent Insiders 36.5 | Percent Institutions 0.22 |
Analyst Ratings
Rating 1 | Target Price 2 | Buy 1 | Strong Buy - |
Buy 1 | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Apollomics Inc. Class A Ordinary Shares
Company Overview
History and Background
Apollomics Inc. is a biopharmaceutical company committed to the discovery, development, and commercialization of oncology therapies. It focuses on developing therapies in areas of unmet medical need in oncology.
Core Business Areas
- Drug Development: Focuses on discovering and developing novel oncology drugs.
- Clinical Trials: Conducts clinical trials to evaluate the safety and efficacy of their drug candidates.
- Commercialization: Prepares for the commercialization of approved therapies, including market access and sales strategies.
Leadership and Structure
Details about the specific leadership team and organizational structure are not readily available without access to current filings or company website. Typically includes a CEO, CFO, CSO, and a board of directors.
Top Products and Market Share
Key Offerings
- APL-101: A targeted therapy for EGFR mutant non-small cell lung cancer. Market share data is currently unavailable. Competitors include AstraZeneca (Tagrisso), Roche (Tarceva).
- APL-106: An EZH2 inhibitor for various hematological malignancies and solid tumors. Market share data is currently unavailable. Competitors include Epizyme (Tazverik).
Market Dynamics
Industry Overview
The oncology market is rapidly growing, driven by an aging population, increased cancer incidence, and advances in targeted therapies and immunotherapies.
Positioning
Apollomics aims to position itself as a key player in the oncology market by developing innovative therapies for specific cancer subtypes. Their focus is on the China market.
Total Addressable Market (TAM)
The global oncology market is estimated to be worth hundreds of billions of dollars. Apollomics is targeting specific segments of this market, positioning it to capture a portion of this TAM.
Upturn SWOT Analysis
Strengths
- Innovative pipeline of oncology drug candidates
- Focus on high unmet medical needs
- Experienced management team
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- Dependence on clinical trial success
- Lack of commercial infrastructure
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new geographic markets
- Acquisition of complementary technologies
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established oncology therapies
- Patent expirations
Competitors and Market Share
Key Competitors
- AZN
- RHHBY
- MRK
- BMY
- GILD
Competitive Landscape
Apollomics faces intense competition from established pharmaceutical companies with larger resources and broader product portfolios. Their success depends on the differentiation and efficacy of their drug candidates.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited due to the company's development stage.
Future Projections: Future growth is dependent on clinical trial success and regulatory approvals. Analyst estimates are not readily available.
Recent Initiatives: Focusing on clinical trials and partnerships to advance drug development programs.
Summary
Apollomics is a development-stage biopharmaceutical company focused on oncology. Their pipeline holds promise, but they face significant risks related to clinical trial outcomes and regulatory approval. They need partnerships to fund development and commercialization. Success is heavily reliant on successfully launching new therapies.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings, Industry reports, Press releases
- Yahoo Finance
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be made based on thorough research and consultation with a qualified financial advisor. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Apollomics Inc. Class A Ordinary Shares
Exchange NASDAQ | Headquaters Foster City, CA, United States | ||
IPO Launch date 2021-11-26 | Co-Founder, CEO & Executive Chairman Dr. Guo-Liang Yu Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 13 | Website https://www.apollomicsinc.com |
Full time employees 13 | Website https://www.apollomicsinc.com | ||
Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer and other solid tumors with MET dysregulation; APL-102, an oral active, small molecule multiple tyrosine kinase inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathways that is in Phase 1 dose escalation clinical trials to treat cancers within the brain. Its immuno-oncology product candidates comprise APL-501, APL-502, and APL-801. The company was founded in 2015 and is based in Foster City, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.